0001246360-19-000743.txt : 20190225
0001246360-19-000743.hdr.sgml : 20190225
20190225155611
ACCESSION NUMBER: 0001246360-19-000743
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190221
FILED AS OF DATE: 20190225
DATE AS OF CHANGE: 20190225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEWIS EARL R
CENTRAL INDEX KEY: 0001230427
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51567
FILM NUMBER: 19629369
MAIL ADDRESS:
STREET 1: C/O NXSTAGE MEDICAL INC. (NXTM)
STREET 2: 439 SOUTH UNION STREET, 5TH FLOOR
CITY: LAWRENCE
STATE: MA
ZIP: 01843
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NxStage Medical, Inc.
CENTRAL INDEX KEY: 0001333170
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 043454702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
BUSINESS PHONE: 978-687-4700
MAIL ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2019-02-21
true
0001333170
NxStage Medical, Inc.
NXTM
0001230427
LEWIS EARL R
350 MERRIMACK STREET
LAWRENCE
MA
01843
true
false
false
false
Common Stock
2019-02-21
4
D
false
100232
30
D
0
D
Stock Option (Right to Buy)
13.16
2019-02-21
4
D
false
23394
0
D
2014-05-22
2024-05-21
Common Stock
23394
0
D
Stock Option (Right to Buy)
16.81
2019-02-21
4
D
false
19724
0
D
2015-06-21
2025-05-20
Common Stock
19724
0
D
Stock Option (Right to Buy)
18.32
2019-02-21
4
D
false
15854
0
D
2016-06-26
2023-05-25
Common Stock
15854
0
D
Stock Option (Right to Buy)
22.78
2019-02-21
4
D
false
15643
0
D
2017-06-25
2024-05-24
Common Stock
15643
0
D
Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
/s/ Aras Lapinskas, attorney-in-fact for Earl Lewis
2019-02-25